Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.

Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR.

Immunity. 2012 Aug 24;37(2):339-50. doi: 10.1016/j.immuni.2012.05.028.

2.

Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration.

Lindemans CA, Calafiore M, Mertelsmann AM, O'Connor MH, Dudakov JA, Jenq RR, Velardi E, Young LF, Smith OM, Lawrence G, Ivanov JA, Fu YY, Takashima S, Hua G, Martin ML, O'Rourke KP, Lo YH, Mokry M, Romera-Hernandez M, Cupedo T, Dow LE, Nieuwenhuis EE, Shroyer NF, Liu C, Kolesnick R, van den Brink MR, Hanash AM.

Nature. 2015 Dec 24;528(7583):560-4. doi: 10.1038/nature16460. Epub 2015 Dec 9.

3.

Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.

Min CK, Maeda Y, Lowler K, Liu C, Clouthier S, Lofthus D, Weisiger E, Ferrara JL, Reddy P.

Blood. 2004 Nov 15;104(10):3393-9. Epub 2004 Jul 27.

4.

IL-22 promoted CD3+ T cell infiltration by IL-22R induced STAT3 phosphorylation in murine acute graft versus host disease target organs after allogeneic bone marrow transplantation.

Zhao K, Ruan S, Tian Y, Zhao D, Chen C, Pan B, Yan Z, Yin L, Zhu S, Xu K.

Int Immunopharmacol. 2016 Oct;39:383-8. doi: 10.1016/j.intimp.2016.08.012. Epub 2016 Aug 20.

PMID:
27551984
5.

Gastrointestinal cells of IL-7 receptor null mice exhibit increased sensitivity to irradiation.

Welniak LA, Khaled AR, Anver MR, Komschlies KL, Wiltrout RH, Durum S, Ruscetti FR, Blazar BR, Murphy WJ.

J Immunol. 2001 Mar 1;166(5):2924-8.

PMID:
11207240
6.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

7.

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL.

J Clin Invest. 1999 Aug;104(4):459-67.

8.

IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.

Couturier M, Lamarthée B, Arbez J, Renauld JC, Bossard C, Malard F, Bonnefoy F, Mohty M, Perruche S, Tiberghien P, Saas P, Gaugler B.

Leukemia. 2013 Jul;27(7):1527-37. doi: 10.1038/leu.2013.39. Epub 2013 Feb 12.

PMID:
23399894
9.

The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells.

Takashima S, Kadowaki M, Aoyama K, Koyama M, Oshima T, Tomizuka K, Akashi K, Teshima T.

J Exp Med. 2011 Feb 14;208(2):285-94. doi: 10.1084/jem.20101559. Epub 2011 Jan 31.

10.

Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M.

J Clin Invest. 1998 Dec 15;102(12):2126-35.

11.

Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR.

J Clin Invest. 1998 Nov 1;102(9):1742-8.

12.
13.

IL-21 is critical for GVHD in a mouse model.

Meguro A, Ozaki K, Oh I, Hatanaka K, Matsu H, Tatara R, Sato K, Leonard WJ, Ozawa K.

Bone Marrow Transplant. 2010 Apr;45(4):723-9. doi: 10.1038/bmt.2009.223. Epub 2009 Aug 31.

14.

Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Lamarthée B, Malard F, Gamonet C, Bossard C, Couturier M, Renauld JC, Mohty M, Saas P, Gaugler B.

Mucosal Immunol. 2016 Mar;9(2):309-21. doi: 10.1038/mi.2015.61. Epub 2015 Jul 8.

PMID:
26153763
15.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.

Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28.

PMID:
18573173
16.

Interleukin-22 aggravates murine acute graft-versus-host disease by expanding effector T cell and reducing regulatory T cell.

Zhao K, Zhao D, Huang D, Yin L, Chen C, Pan B, Wu Q, Li Z, Yao Y, Shen E, Zeng L, Xu K.

J Interferon Cytokine Res. 2014 Sep;34(9):707-15. doi: 10.1089/jir.2013.0099. Epub 2014 Apr 10.

PMID:
24720737
17.

Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease.

Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R, Drobyski WR.

J Immunol. 2004 Mar 1;172(5):3328-36.

18.

Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease.

Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR.

Blood. 2009 Mar 5;113(10):2352-62. doi: 10.1182/blood-2008-08-175448. Epub 2008 Dec 4.

19.

In vivo administration of interleukin-6 in murine allogeneic bone marrow chimeras: early and delayed enhancement of hematopoiesis accompanied with split tolerance but not with graft-versus-host disease.

Imamura M, Hashino S, Kobayashi H, Tanaka J, Imai K, Han M, Fujii Y, Kobayashi M, Higa T, Kasai M, et al.

Immunobiology. 1994 Jun;190(4-5):346-67.

PMID:
7982720
20.

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.

Nat Med. 2003 Sep;9(9):1144-50. Epub 2003 Aug 17.

PMID:
12925844

Supplemental Content

Support Center